Literature DB >> 32539305

Absolute Change in High Sensitivity Cardiac Troponin I for Three Hours is Useful for Diagnosing Acute Myocardial Infarction in the Emergency Department: How to Get to Best Benefit From HS-Troponins in Clinical Practice?

Fabien Huet1,2, Anne Marie Dupuy3, Jean Paul Cristol2,3, François Roubille1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32539305      PMCID: PMC7295961          DOI: 10.3343/alm.2020.40.6.488

Source DB:  PubMed          Journal:  Ann Lab Med        ISSN: 2234-3806            Impact factor:   3.464


× No keyword cloud information.
Dear Editor, The latest generation of troponin assays, the high-sensitivity (hs)-cardiac troponins (hs-cTn), provide a powerful tool for the diagnosis and management of patients with suspected acute myocardial infarction (AMI). However, these assays are a double-edged sword, as although they are very sensitive, their results can sometimes be misleading. For instance, hs-cTn do not follow the classical decrease exhibited by other traditional biomarkers such as creatine kinase or non-hs-cTn markers [1]. Thus, physicians should be aware of these characteristics to avoid misinterpretation. In addition, for clinical research purposes, although the management and interpretation of hs-cTn are sometimes tricky, they can also provide unexpected assessments such as an approximation of microvascular occlusion [2,3]. In other words, hs-cTn constitutes a powerful tool that should be used extensively but cautiously. In a paper by Kim, et al. [4] entitled “Absolute change in high sensitivity cardiac troponin I for 3 hours is useful for diagnosing AMI in the emergency department (ED)”, the authors proposed a smart use of hs-cTn value; briefly, they emphasize that using the absolute change of the cardiac hs-cTnI value to diagnose AMI in the ED is better than using the relative change, expressed as % of baseline. Although this finding is not completely novel [5, 6], it warrants further exploration. First, some limitations need to be updated, especially the lack of applicability for other biomarkers including other subtypes of hs-cTn. In addition, the results should be considered with caution, as they were obtained from a single center, with a relatively small population. The current guidelines recommend the use of relative rather than absolute changes in hs-cTn value to define a recognized pattern of change (changes from 20–60%) [7]. Importantly, absolute changes of hs-cTn values are not recommended because they are assay dependent; the cut-offs are specifically defined for each assay, based on the 0–1 hour kinetics, and the use of this strategy should be restricted to a very short list of manufacturers. Thus, this study provides important data, not only by emphasizing the importance of the absolute change in hs-cTnI values, but also by suggesting a standard delay of three hours between assays. These results could be of interest, especially during very early admission to the ED or for specific subpopulations but need to be further explored. For instance, could this absolute elevation be more relevant in elderly patients or patients with chronic kidney disease, known to have high baseline troponins, clearly associated with long-term mortality [8]? Importantly, the negative predictive value (NPV) appears to be good in various studies but decreases significantly when very short delays are considered [9]. Interestingly, some authors have established similar NPVs for hs-cTn I or T using various assays [6], while others have suggested less perfect NPVs (96.5%) using an hs-cTnT assay or more importantly when the delay is very short (<1 hour) [10]. Indeed, from a clinical standpoint, a near 100% NPV is mandatory in order to safely rule out suspected patients. In conclusion, clinicians should be aware of this specific issue in order to improve patient management, especially in difficult, real-life clinical setting cases.
  9 in total

1.  Estimation of age- and comorbidities-adjusted percentiles of high-sensitivity cardiac troponin T levels in the elderly.

Authors:  Nils Kuster; Karine Monnier; Gregory Baptista; Anne-Marie Dupuy; Stéphanie Badiou; Anne-Sophie Bargnoux; Claude Jeandel; Jean-Paul Cristol
Journal:  Clin Chem Lab Med       Date:  2015-04       Impact factor: 3.694

Review 2.  Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays.

Authors:  Christian Mueller; Raphael Twerenbold; Tobias Reichlin
Journal:  Clin Chem       Date:  2019-01-07       Impact factor: 8.327

3.  An hs-TNT Second Peak Associated with High CRP at Day 2 Appears as Potential Biomarkers of Micro-Vascular Occlusion on Magnetic Resonance Imaging after Reperfused ST-Segment Elevation Myocardial Infarction.

Authors:  Fabien Huet; Mariama Akodad; Nils Kuster; Hélène Kovacsik; Florence Leclercq; Anne-Marie Dupuy; Richard Gervasoni; Gisele Khoury; Jean Christophe Macia; Jean-Paul Cristol; François Roubille
Journal:  Cardiology       Date:  2018-08-23       Impact factor: 1.869

4.  Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction.

Authors:  Tobias Reichlin; Affan Irfan; Raphael Twerenbold; Miriam Reiter; Willibald Hochholzer; Hanna Burkhalter; Stefano Bassetti; Stephan Steuer; Katrin Winkler; Federico Peter; Julia Meissner; Philip Haaf; Mihael Potocki; Beatrice Drexler; Stefan Osswald; Christian Mueller
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

5.  "30-minute-delta" of high-sensitivity troponin I improves diagnostic performance in acute myocardial infarction.

Authors:  Hiroaki Yokoyama; Takumi Higuma; Tomohide Endo; Fumie Nishizaki; Kenji Hanada; Takashi Yokota; Masahiro Yamada; Ken Okumura; Hirofumi Tomita
Journal:  J Cardiol       Date:  2017-09-21       Impact factor: 3.159

6.  Which high-sensitivity troponin variable best characterizes infarct size and microvascular obstruction?

Authors:  Mathieu Schaaf; Fabien Huet; Mariama Akodad; Anne-Marie Gorce-Dupuy; Jérôme Adda; Jean-Christophe Macia; Delphine Delseny; Florence Leclercq; Jean-Paul Cristol; Gregory Marin; Nathan Mewton; François Roubille
Journal:  Arch Cardiovasc Dis       Date:  2019-02-15       Impact factor: 2.340

7.  Kinetics of high-sensitivity cardiac troponin T and I differ in patients with ST-segment elevation myocardial infarction treated by primary coronary intervention.

Authors:  Guillaume Laugaudin; Nils Kuster; Amael Petiton; Florence Leclercq; Richard Gervasoni; Jean-Christophe Macia; Thien-Tri Cung; Anne-Marie Dupuy; Kamila Solecki; Benoit Lattuca; Stéphane Cade; Frédéric Cransac; Jean-Paul Cristol; François Roubille
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2015-05-05

8.  Early diagnosis of myocardial infarction using absolute and relative changes in cardiac troponin concentrations.

Authors:  Affan Irfan; Tobias Reichlin; Raphael Twerenbold; Marc Meister; Berit Moehring; Karin Wildi; Stefano Bassetti; Christa Zellweger; Maria Rubini Gimenez; Rebeca Hoeller; Karsten Murray; Seoung Mann Sou; Mira Mueller; Tamina Mosimann; Miriam Reiter; Philip Haaf; Ronny Ziller; Heike Freidank; Stefan Osswald; Christian Mueller
Journal:  Am J Med       Date:  2013-07-18       Impact factor: 4.965

9.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

Authors:  Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.